Iterum Therapeutics Plc (NASDAQ: ITRM) is -27.41% lower on its value in year-to-date trading and has touched a low of $0.71 and a high of $2.50 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ITRM stock was last observed hovering at around $1.48 in the last trading session, with the day’s loss setting it -0.05%.
Currently trading at $1.43, the stock is 9.75% and 24.95% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.29 million and changing -3.38% at the moment leaves the stock 7.27% off its SMA200. ITRM registered 81.01% gain for a year compared to 6-month loss of -4.67%. The firm has a 50-day simple moving average (SMA 50) of $1.13744 and a 200-day simple moving average (SMA200) of $1.33136.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 40.20% gain in the last 1 month and extending the period to 3 months gives it a 18.18%, and is 17.21% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.52% over the week and 16.41% over the month.
Iterum Therapeutics Plc (ITRM) has around 14 employees, a market worth around $32.46M and $0.00M in sales. Distance from 52-week low is 102.84% and -42.80% from its 52-week high.
The EPS is expected to grow by 68.93% this year
19.0 institutions hold shares in Iterum Therapeutics Plc (ITRM), with institutional investors hold 3.10% of the company’s shares. The shares outstanding are 22.71M, and float is at 21.95M with Short Float at 11.54%. Institutions hold 3.05% of the Float.
The top institutional shareholder in the company is BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC with over 66.0 shares valued at $76.0. The investor’s holdings represent 0.0004 of the ITRM Shares outstanding.
Iterum Therapeutics Plc (ITRM) Insider Activity
The most recent transaction is an insider purchase by Dunne Michael W., the company’s Director. SEC filings show that Dunne Michael W. bought 25,000 shares of the company’s common stock on Dec 22 ’23 at a price of $1.40 per share for a total of $35000.0. Following the purchase, the insider now owns 0.11 million shares.
Iterum Therapeutics Plc disclosed in a document filed with the SEC on Dec 18 ’23 that Dunne Michael W. (Director) bought a total of 10,000 shares of the company’s common stock. The trade occurred on Dec 18 ’23 and was made at $1.84 per share for $18442.0. Following the transaction, the insider now directly holds 88754.0 shares of the ITRM stock.
Still, SEC filings show that on Nov 22 ’23, Dunne Michael W. (Director) acquired 20,000 shares at an average price of $2.03 for $40690.0. The insider now directly holds 78,754 shares of Iterum Therapeutics Plc (ITRM).
